GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anhui Anke Biotechnology (Group) Co Ltd (SZSE:300009) » Definitions » EBIT

Anhui Anke Biotechnology (Group) Co (SZSE:300009) EBIT : ¥805 Mil (TTM As of Dec. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Anhui Anke Biotechnology (Group) Co EBIT?

Anhui Anke Biotechnology (Group) Co's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2024 was ¥105 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2024 was ¥805 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Anhui Anke Biotechnology (Group) Co's annualized ROC % for the quarter that ended in Dec. 2024 was 16.49%. Anhui Anke Biotechnology (Group) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 24.89%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Anhui Anke Biotechnology (Group) Co's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2024 was 7.02%.


Anhui Anke Biotechnology (Group) Co EBIT Historical Data

The historical data trend for Anhui Anke Biotechnology (Group) Co's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anhui Anke Biotechnology (Group) Co EBIT Chart

Anhui Anke Biotechnology (Group) Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 417.20 296.66 835.37 921.80 805.42

Anhui Anke Biotechnology (Group) Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 152.79 258.49 234.97 206.90 105.06

Competitive Comparison of Anhui Anke Biotechnology (Group) Co's EBIT

For the Biotechnology subindustry, Anhui Anke Biotechnology (Group) Co's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anhui Anke Biotechnology (Group) Co's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anhui Anke Biotechnology (Group) Co's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Anhui Anke Biotechnology (Group) Co's EV-to-EBIT falls into.


;
;

Anhui Anke Biotechnology (Group) Co EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥805 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anhui Anke Biotechnology (Group) Co  (SZSE:300009) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Anhui Anke Biotechnology (Group) Co's annualized ROC % for the quarter that ended in Dec. 2024 is calculated as:

ROC % (Q: Dec. 2024 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2024 ) + Invested Capital (Q: Dec. 2024 ))/ count )
=455.536 * ( 1 - -10.67% )/( (3052.552 + 3062.88)/ 2 )
=504.1416912/3057.716
=16.49 %

where

Invested Capital(Q: Sep. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=4990.978 - 668.589 - ( 1269.837 - max(0, 699.755 - 2240.715+1269.837))
=3052.552

Invested Capital(Q: Dec. 2024 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=5135.35 - 628.591 - ( 1443.879 - max(0, 667.585 - 2275.096+1443.879))
=3062.88

Note: The Operating Income data used here is four times the quarterly (Dec. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

Anhui Anke Biotechnology (Group) Co's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2024 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2024 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2024  Q: Dec. 2024
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=420.24/( ( (1492.993 + max(201.653, 0)) + (1583.613 + max(98.906, 0)) )/ 2 )
=420.24/( ( 1694.646 + 1682.519 )/ 2 )
=420.24/1688.5825
=24.89 %

where Working Capital is:

Working Capital(Q: Sep. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(509.651 + 305.679 + 72.952) - (668.589 + 0 + 18.04)
=201.653

Working Capital(Q: Dec. 2024 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(442.318 + 297.296 + 11.163) - (628.591 + 0 + 23.28)
=98.906

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Anhui Anke Biotechnology (Group) Co's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2024 )
=805.422/11480.389
=7.02 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Anhui Anke Biotechnology (Group) Co EBIT Related Terms

Thank you for viewing the detailed overview of Anhui Anke Biotechnology (Group) Co's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Anhui Anke Biotechnology (Group) Co Business Description

Traded in Other Exchanges
N/A
Address
No.9 Changjiang Road, Hefei High-tech Zone, Customs Road 669, Hefei, CHN, 230088
Anhui Anke Biotechnology (Group) Co Ltd is engaged in the development, manufacture, and sale of pharmaceuticals and health-care products. The Company distributes its product in both domestic and overseas markets. The company operates in more than 30 provinces in China.
Executives
Zhao Hui Directors, executives
Zhou Yuan Yuan Directors, executives
Wang Yong Supervisors
Yao Jian Ping Executives
Wang Rong Hai Directors, executives
Song She Wu Directors, executives
Fu Yong Biao Directors, executives
Jiang Jun Pei Supervisors
Xu Zhen Shan Director
Lu Guang Xin Executives
Yan Xin Wen Executives
Lu Chun Yan Executives
Wu Rui Director
Fan Qing Lin Director
Wang Yong Bin Executives

Anhui Anke Biotechnology (Group) Co Headlines

No Headlines